The comparative efficacy of FDA-approved drugs for management of alcohol use disorder ‒ a network meta-analysis
DOI:
https://doi.org/10.15584/ejcem.2025.4.15Keywords:
acamprosate, alcohol use disorder, disulfiram, meta-analysis, naltrexone, randomized controlled trialAbstract
Introduction and aim. Alcohol use disorder (AUD) represents a significant and lasting public health challenge affecting millions of people around the world. Currently, the US FDA has approved naltrexone, disulfiram, and acamprosate for AUD; however, their comparative effectiveness remains uncertain. This study aimed to evaluate the comparative efficacy of FDA-approved medications for AUD.
Material and methods. A comprehensive search of PubMed, the Cochrane Library, and Embase was performed up to January 2025. Eligible studies were randomized controlled trials of at least 12 weeks in duration, enrolling adults with AUD and investigating one or more FDA-approved medications, individually or in combination. The Cochrane Risk of Bias 2 (ROB 2) tool was used to assess study quality. A frequentist random-effects network meta-analysis (NMA) was performed. The primary and secondary outcomes were the return to any level of drinking and the return to heavy drinking, respectively.
Analysis of the literature. Fifty-two trials were included. Compared to placebo, acamprosate (risk ratio, RR, 0.87 [95% CI, 0.82-0.92]), naltrexone (0.93 [0.88-0.99]) and a combination of acamprosate and naltrexone (NAAC) (0.52 [0.35-0.76]) all statistically significantly reduced the risk of return to any type of drinking. Based on SUCRA rankings, NAAC (SUCRA = 0.99) was ranked first for efficacy. For the secondary outcome, only naltrexone (RR, 0.87 [0.80-0.95]) was found to be effective.
Conclusion. When combined with psychosocial interventions, naltrexone and acamprosate demonstrated superior efficacy compared to placebo. Furthermore, the combination of the two medications led to significantly better results.
Downloads
References
Alcohol Use Disorder Guidelines. National Institute on Alcohol Abuse and Alcoholism. 2019. https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking. Accessed May 2, 2025.
Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987-1012. doi: 10.1016/S2215-0366(18)30337-7
Roerecke M, Rehm J. Alcohol use disorders and mortality: a systematic review and meta-analysis. Addiction. 2013;108(9):1562-1578. doi: 10.1111/add.12231
Roerecke M, Gual A, Rehm J. Reduction of alcohol consumption and subsequent mortality in alcohol use disorders: systematic review and meta-analyses. J Clin Psychiatry. 2013;74(12):e1181-1189. doi: 10.4088/JCP.13r08379
McPheeters M, O’Connor EA, Riley S, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023;330(17):1653-1665. doi: 10.1001/jama.2023.19761
Agabio R, Lopez-Pelayo H, Bruguera P, et al. Efficacy of medications for the treatment of alcohol use disorder (AUD): A systematic review and meta-analysis considering baseline AUD severity. Pharmacol Res. 2024;209:107454. doi: 10.1016/j.phrs.2024.107454
Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293. doi: 10.1111/j.1360-0443.2012.04054.x
Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25(9):1335-1341.
Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110(6):920-930. doi: 10.1111/add.12875
Carmen B, Angeles M, Ana M, María AJ. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811-828. doi: 10.1111/j.1360-0443.2004.00763.x
Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical Tools for Network Meta-Analysis in STATA. PLOS ONE. 2013;8(10):e76654. doi: 10.1371/journal.pone.0076654
Bahji A, Bach P, Danilewitz M, et al. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. J Addict Med. 2022;16(6):630-638. doi: 10.1097/ADM.0000000000000992
Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220-237. doi: 10.1111/add.13974
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. doi: 10.7326/M14-2385
Yaseen W, Mong J, Zipursky J. Sobering Perspectives on the Treatment of Alcohol Use Disorder. JAMA Netw Open. 2024;7(3):e243340. doi: 10.1001/jamanetworkopen.2024.3340
Agabio R, Saulle R, Rösner S, Minozzi S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2023;1(1):CD012557. doi: 10.1002/14651858.CD012557.pub3
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (Editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024). Cochrane, 2024. Available from Www.Cochrane.Org/Handbook. Accessed May 2, 2025.
Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Methods for Effective Health Care. Agency for Healthcare Research and Quality (US); 2008. http://www.ncbi.nlm.nih.gov/books/NBK91433/. Accessed July 15, 2025.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi: 10.1016/0197-2456(86)90046-2
Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932-944. doi: 10.1002/sim.3767
Veroniki AA, Vasiliadis HS, Higgins JPT, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42(1):332-345. doi: 10.1093/ije/dys222
Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163-171. doi: 10.1016/j.jclinepi.2010.03.016
Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLOS Medicine. 2020;17(4):e1003082. doi: 10.1371/journal.pmed.1003082
Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev. 2020;16(1):e1080. doi: 10.1002/cl2.1080
Anton RF, Moak DH, Latham P, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25(4):349-357. doi: 10.1097/01.jcp.0000172071.81258.04
Mann K, Lemenager T, Hoffmann S, et al. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013;18(6):937-946. doi: 10.1111/adb.12012
Wölwer W, Frommann N, Jänner M, et al. The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. Drug Alcohol Depend. 2011;118(2-3):417-422. doi: 10.1016/j.drugalcdep.2011.05.001
Anton RF, O’Malley SS, Ciraulo DA, et al. Combined Pharmacotherapies and Behavioral Interventions for Alcohol DependenceThe COMBINE Study: A Randomized Controlled Trial. JAMA. 2006;295(17):2003-2017. doi: 10.1001/jama.295.17.2003
Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451-1462. doi: 10.1111/j.1360-0443.2006.01555.x
Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60(1):92-99. doi: 10.1001/archpsyc.60.1.92
Alkermes, Inc. Efficacy and Safety of VIVITROL® in Adults Completing Inpatient Treatment for Alcohol Dependence. clinicaltrials.gov; 2011. https://clinicaltrials.gov/study/NCT00501631. Accessed July 15, 2025.
Brown ES, Carmody TJ, Schmitz JM, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33(11):1863-1869. doi: 10.1111/j.1530-0277.2009.01024.x
Huang MC, Chen CH, Yu JM, Chen CC. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol. 2005;10(3):289-292. doi: 10.1080/13556210500223504
Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530-534. doi: 10.5694/j.1326-5377.2002.tb04550.x
Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and Cue Exposure With Coping and Communication Skills Training for Alcoholics: Treatment Process and 1-Year Outcomes. Alcohol Clin Exp Res. 2001;25(11):1634-1647. doi: 10.1111/j.1530-0277.2001.tb02170.x
Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol DependenceA Randomized Controlled Trial. JAMA. 2005;293(13):1617-1625. doi: 10.1001/jama.293.13.1617
Kranzler HR, Wesson DR, Billot L, DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28(7):1051-1059. doi: 10.1097/01.alc.0000130804.08397.29
Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167(6):668-675. doi: 10.1176/appi.ajp.2009.08060852
Oslin DW, Lynch KG, Pettinati HM, et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res. 2008;32(7):1299-1308. doi: 10.1111/j.1530-0277.2008.00698.x
Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008;103(12):2035-2044. doi: 10.1111/j.1360-0443.2008.02355.x
O’Malley SS, Robin RW, Levenson AL, et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res. 2008;32(7):1271-1283. doi: 10.1111/j.1530-0277.2008.00682.x
O’Malley SS, Sinha R, Grilo CM, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007;31(4):625-634. doi: 10.1111/j.1530-0277.2007.00347.x
Killeen TK, Brady KT, Gold PB, et al. Effectiveness of Naltrexone in a Community Treatment Program. Alcohol Clin Exp Res. 2004;28(11):1710-1717. doi: 10.1097/01.ALC.0000145688.30448.2C
Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27(7):1142-1149. doi: 10.1097/01.ALC.0000075548.83053.A9
Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381-1387. doi: 10.1097/01.ALC.0000030561.15921.A9
Ahmadi J, Ahmadi N. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. German Journal of Psychiatry. 2002;5.
Gastpar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22(6):592-598. doi: 10.1097/00004714-200212000-00009
Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565-1573. doi: 10.1046/j.1360-0443.2001.961115654.x
Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739. doi: 10.1056/NEJMoa011127
Lee A, Tan S, Lim D, et al. Naltrexone in the treatment of male alcoholics-an effectiveness study in Singapore. Drug and Alcohol Review. 2001;20(2):193-199. doi: 10.1080/09595230124192
Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758-1764. doi: 10.1176/ajp.156.11.1758
Oslin D, Liberto JG, O’Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry. 1997;5(4):324-332. doi: 10.1097/00019442-199700540-00007
Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737-742. doi: 10.1001/archpsyc.1997.01830200071010
Volpicelli JR, Clay KL, Watson NT, O’Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry. 1995;56(7):39-44.
O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881-887. doi: 10.1001/archpsyc.1992.01820110045007
Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57(10):1128-1137. doi: 10.1016/j.biopsych.2005.02.016
Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann Intern Med. 1979;90(6):901-904. doi: 10.7326/0003-4819-90-6-901
Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256(11):1449-1455.
Higuchi S, Japanese Acamprosate Study Group. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). J Clin Psychiatry. 2015;76(2):181-188. doi: 10.4088/JCP.13m08940
Berger L, Fisher M, Brondino M, et al. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study. Alcohol Clin Exp Res. 2013;37(4):668-674. doi: 10.1111/acer.12010
Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40(5):383-393. doi: 10.1016/j.jpsychires.2006.02.002
Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol. 2004;65(1):136-139. doi: 10.15288/jsa.2004.65.136
Gual A, Lehert P. Acamprosate During And After Acute Alcohol Withdrawal: A Double-Blind Placebo-Controlled Study In Spain. Alcohol Alcohol. 2001;36(5):413-418. doi: 10.1093/alcalc/36.5.413
Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35(2):176-187. doi: 10.1093/alcalc/35.2.176
Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587-593. doi: 10.1093/alcalc/35.6.587
Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35(2):202-209. doi: 10.1093/alcalc/35.2.202
Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22(3):573-579. doi: 10.1111/j.1530-0277.1998.tb04295.x
Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and Prevention of Relapse in Alcoholics: Results of a Randomized, Placebo-Controlled, Double-Blind Study in Out-Patient Alcoholics in the Netherlands, Belgium and Luxembourg. European Addiction Research. 2009;3(3):129-137. doi: 10.1159/000259166
Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77. doi: 10.1192/bjp.171.1.73
Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92(11):1537-1546. doi: 10.1111/j.1360-0443.1997.tb02873.x
Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53(8):673-680. doi: 10.1001/archpsyc.1996.01830080023006
Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347(9013):1438-1442. doi: 10.1016/s0140-6736(96)91682-7
Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239-247.
Pelc I, Le Bon O, Verbanck P, Lehert Ph, Opsomer L. Calcium-Acetylhomotaurinate for Maintaining Abstinence in Weaned Alcoholic Patients: A Placebo-Controlled Double-Blind Multicenter Study. In: Naranjo CA, Sellers EM, eds. Novel Pharmacological Interventions for Alcoholism. Springer; 1992:348-352. doi: 10.1007/978-1-4612-2878-3_44
Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25(6):613-622. doi: 10.1093/oxfordjournals.alcalc.a045057
Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 1985;1(8436):1014-1016. doi: 10.1016/s0140-6736(85)91615-0
Mar Y, Whitley SD, Weigand TJ, Stancliff SL, Gonzalez CJ, Hoffmann CJ. Treatment of Alcohol Use Disorder. Johns Hopkins University; 2023. http://www.ncbi.nlm.nih.gov/books/NBK561234/. Accessed July 15, 2025.
Yoshimura A, Kimura M, Nakayama H, et al. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res. 2014;38(2):572-578. doi: 10.1111/acer.12278
Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010;9(1):13-22. doi: 10.2174/187152710790966704
Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77(2):315-323. doi: 10.1111/bcp.12070
Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl. 2005;(15):148-156. doi: 10.15288/jsas.2005.s15.148
Kiefer F, Wiedemann K. Combined Therapy: What Does Acamprosate And Naltrexone Combination Tell Us? Alcohol Alcohol. 2004;39(6):542-547. doi: 10.1093/alcalc/agh093
Ndegwa S. Naltrexone in Combination with Acamprosate for the Treatment of Alcohol Dependence a Review of the Clinical and Cost-Effectiveness. [desLibris e-book]. Canadian Agency for Drugs and Technologies in Health; 2009.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
